Journal of Surgical Oncology最新文献

{"title":"Impact of Neoadjuvant Approach and Tumor Response on Survival in Pancreatic Adenocarcinoma.","authors":"Mohammed O Suraju, Brian Longbottom, Jasmine A Peterson, Terry Hayes, Kiers Brevik, Sean Y Kim, Paolo Goffredo, Imran Hassan, Hassan Aziz, Carlos H F Chan","doi":"10.1002/jso.70329","DOIUrl":"https://doi.org/10.1002/jso.70329","url":null,"abstract":"<p><strong>Introduction: </strong>Neoadjuvant therapy for pancreatic adenocarcinoma (PDAC) has evolved from single-agent to multi-agent approaches, largely informed by metastatic disease studies demonstrating improved survival; albeit at the price of increased toxicity. It remains unclear how response to varied neoadjuvant regimens impact survival. We hypothesized that tumor response to different neoadjuvant approaches reflects underlying tumor biology, and achieving a pathologic complete response (pCR) with single-agent neoadjuvant may signal favorable biology.</p><p><strong>Methods: </strong>Adult PDAC patients (2010-2021) who received neoadjuvant therapy were identified in the National Cancer Database. Tumor response was categorized as pCR (pT0N0), moderate (≥ 2 T-stage reduction), or minimal/no response (≤ 1 T-stage reduction). Patients with stage IV disease, margin positive, or nodal involvement on final pathology were excluded; sensitivity analyses including these patients were performed. Neoadjuvant regimens were classified as single-agent, multi-agent, or multi-agent therapy plus adjuvant chemotherapy.</p><p><strong>Results: </strong>Of 1923 patients, 9.8% achieved pCR, 19.1% had moderate response and 71.1% had minimal/no response. The 3-year overall survival (OS) was 74% [68-81] for pCR, 56% [51-62] for moderate, and 50% [47-52] for minimal/no response. Notably, 11% of pCR patients received single-agent therapy and had a 3-year OS comparable to those who received more intensive regimens, even after adjusting for confounders. Conversely, single-agent therapy in moderate or minimal/no responders was associated with significantly worse survival. Sensitivity analyses including patients with nodal metastasis and positive margins demonstrated consistent trends.</p><p><strong>Conclusions: </strong>Most PDAC patients benefit from multi-agent neoadjuvant, although a small subset achieve pCR with single-agent therapy and experience excellent outcomes. Response to varied neoadjuvant approaches merits further investigation in biomarker-driven studies and may inform opportunities for therapy personalization in appropriately selected PDAC patients.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148887803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"'Posterior (SMA-first) Approach' Versus 'Standard Approach' in Terms of Resection Margin and Long-Term Survival After Pancreaticoduodenectomy for Periampullary and Pancreatic Carcinoma: A Randomized Trial.","authors":"Hemant Ashok Jain, Gursagar Singh Sahota, Anand Narayan Singh, Rajni Yadav, Prasenjit Das, Nihar Ranjan Dash, Kumble Seetharama Madhusudhan, Siddhartha Dattagupta, Sujoy Pal","doi":"10.1002/jso.70347","DOIUrl":"https://doi.org/10.1002/jso.70347","url":null,"abstract":"<p><strong>Introduction: </strong>SMA-first-approach in pancreaticooduodenectomy (PD) was found to be associated with better oncological outcomes as compared to the standard approach both in our pilot study and a few retrospective studies. Hence, we performed a randomized controlled trial to compare these two approaches in terms of resection margins, lymph node-retrieval, and long-term survival.</p><p><strong>Methods: </strong>Between January 2014 to December 2018, all the consecutive patients undergoing PD for periampullary cancer at the Department of Gastrointestinal Surgery, AIIMS, New Delhi were assessed for randomization. Primary outcomes were R0 resection rate and number of lymph nodes retrieved. The secondary outcomes were operating time, blood loss, postoperative complications, recurrence free and overall survival.</p><p><strong>Results: </strong>Of 299 patients assessed, 203 were randomized and 183 analyzed (20: excluded after randomization, 90: patients-SMA, 93: patients-classical). The median age of the study population was 56 (14-78) years, with predominantly male (138, 68%) and with periampullary tumors (89%). The demographic profile, preoperative clinical and laboratory parameters were comparable. The blood loss was significantly higher in SMA first group (675 vs 600 ml, p = 0.02), however the operating time and the need for blood transfusion were comparable in both groups. ISGPS Grade B/C pancreatojejunostomy leak (20 vs 24.7%, p = 0.68), post-pancreatectomy hemorrhage (8.8 vs 14%, p = 0.38), delayed gastric emptying (37.8 vs 40.9%, p = 0.67) and Clavien-Dindo grade ≥III complications(27.7 vs 31.2, p = 0.85) were similar in both the groups. The R0 resection rates (82.2 vs 78.5%, p = 0.53) and total lymphnodes retrieved (18 vs 17, p = 0.63) were similar between the two groups. Both groups were comparable in terms of median recurrence free (48 vs 44 months, p = 0.85) and overall survival (53 vs 51 months, p = 0.69).</p><p><strong>Conclusions: </strong>'Posterior (SMA-first) approach' and 'Standard approach' for pancreatoduodenectomy for periampullary cancer yielded equivalent results in terms of R0 resection rate, number of lymph nodes retrieved, recurrence-free and overall-survival.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148887811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunogenic Cell Death-Associated miRNAs in the Tumor Microenvironment of Hepatocellular Carcinoma.","authors":"Anrong Jiang, Yun-Qi Mo, Ying Wang, Kuncheng Qiu, Yi-Ran Ni, Lan Ma, Rui-Tao Zhang, Yan-Qiong Zhang, Jiangfeng Wu, Bo-Tao Li","doi":"10.1002/jso.70363","DOIUrl":"https://doi.org/10.1002/jso.70363","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) poses significant therapeutic challenges due to its high heterogeneity and immunosuppressive tumor microenvironment (TME). Immunogenic cell death (ICD) represents a promising strategy in cancer therapy by eliciting antitumor immune responses through the controlled release of damage-associated molecular patterns (DAMPs). However, its therapeutic efficacy remains substantially limited by the immunosuppressive TME and the lack of selective targeting of conventional ICD-inducing agents. MicroRNAs (miRNAs) regulate immune checkpoints (e.g., PD-L1), TME populations (e.g., tumor-associated macrophages and regulatory T cells), and DAMPs-related pathways, positioning them to both enhance ICD and relieve its constraints. Clinical translation, however, is hindered by delivery and off-target effects. Emerging nanotechnologies, including pH-responsive and photoresponsive carriers, enable spatiotemporal co-delivery of ICD inducers (e.g., oxaliplatin) and miRNA modulators (e.g., anti-miR-21), thereby augmenting DAMP release, reprogramming the TME, and targeting competing endogenous RNA networks (e.g., lncRNA H19) to overcoming resistance. In this Review, with a focus on clinical translation, we argue that combining ICD, immune checkpoint blockade, and miRNA modulation offers a coherent framework to turn cold HCC tumors into responsive ones, thereby increasing treatment precision and sustaining benefit.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148887860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Advanced Age on Functional Recovery Following Glossectomy.","authors":"Jenny Chen, Ayana Cole-Price, Brianna M Peet, Kyeong-Tae Lee, Geoffrey E Hespe, Lillian A Boe, Louise Cunningham, Farooq Shahzad, Marc A Cohen, Jennifer R Cracchiolo, Jonas A Nelson, Evan Matros, Robert J Allen","doi":"10.1002/jso.70355","DOIUrl":"https://doi.org/10.1002/jso.70355","url":null,"abstract":"<p><strong>Background: </strong>Glossectomy for oral cancer can lead to significant concerns regarding speech and swallowing function. This study aims to assess the impact of age on post-glossectomy functional recovery and quality of life.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of patients who underwent glossectomy for primary oral cavity cancer involving the oral tongue from 2016 to 2024. Patients were stratified into three cohorts: < 60, 60-70, and > 70 years. Functional outcomes were assessed using speech-language pathology evaluations at 1 month, 6 months, 1 year, and 2 years postoperatively. Patient-reported quality of life was assessed using FACE-Q scores.</p><p><strong>Results: </strong>206 patients were included, with 92 patients under 60, 61 patients aged 60-70, and 53 patients over 70. Primary closure was performed in 80 patients (39%), and free flap reconstruction in 109 (53%). One month postoperatively, patients over 70 demonstrated significantly higher rates of moderate to severe reductions in labial ROM and strength (p < 0.05). At 1 and 2 years, most functional differences had resolved, but deficits in labial ROM and strength persisted at 2 years (p = 0.048). FACE-Q scores, gastrostomy tube and tracheostomy dependence, length of stay, readmission, reoperation, and revision rates did not differ across cohorts. When adjusting for comorbidities, glossectomy type and age were significant predictors of long-term functional outcomes.</p><p><strong>Conclusion: </strong>Older patients undergoing glossectomy may experience initial delays in functional recovery, but long-term clinically meaningful functional outcomes are comparable across age groups. However, older patients may experience decreased patient-reported satisfaction in key domains, emphasizing the need for careful patient selection and shared decision-making when considering glossectomy in older adults.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148887846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Morbidity and Mortality of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients Aged 70 Years and Older: A Two-Center 10-Year Experience.","authors":"Ali Ediz Kıvanç, Mehmet Oduncu, Pırıltı Özcan, Özgül Düzgün, Neşet Köksal","doi":"10.1002/jso.70393","DOIUrl":"https://doi.org/10.1002/jso.70393","url":null,"abstract":"<p><strong>Background and objectives: </strong>Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is established for peritoneal surface malignancies, but its use in older patients is debated. We assessed CRS-HIPEC morbidity and mortality in patients aged ≥ 70 years using a cohort of younger patients as a comparator.</p><p><strong>Methods: </strong>We retrospectively reviewed consecutive patients aged ≥ 70 and < 70 undergoing CRS-HIPEC for peritoneal carcinomatosis at two centers (2017-2026). Peritoneal carcinomatosis index (PCI), completeness of cytoreduction (CC), complications (Clavien-Dindo), and mortality were analyzed.</p><p><strong>Results: </strong>Ninety-five patients were included (53 female; mean age 74.7 years; 10 [10.5%] aged ≥ 80; 70 [73.7%] ASA III-IV). Commonest primaries: colorectal (40), gastric (14), ovarian (12). Mean PCI was 15.6; complete cytoreduction (CC-0) was achieved in 58.9%. Complications were Clavien-Dindo grade III-IV in 11.6%, and grade V in 3.2%; major morbidity (≥ III) was 14.7%. Longer operative time (p = 0.013) and intraoperative transfusion (p = 0.027) were associated with major morbidity in the elderly cohort, whereas age was not (p = 0.161). Overall mortality was 12/95 (12.6%).</p><p><strong>Conclusions: </strong>In selected patients aged ≥ 70 years, CRS-HIPEC achieved morbidity and mortality comparable to the younger group, with most complications low-grade. Advanced age alone should not preclude CRS-HIPEC; candidacy depends on comorbidity, performance status, and the likelihood of complete cytoreduction.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148880917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Parotidectomy: 10-Year Experience in the Hands of Surgical Oncologists","authors":"Audrey Y. Su,&nbsp;James Koness,&nbsp;Abdul S. Calvino,&nbsp;Ponnandai Somasundar,&nbsp;Steve Kwon","doi":"10.1002/jso.70297","DOIUrl":"10.1002/jso.70297","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Objectives</h3>\u0000 \u0000 <p>Parotidectomy is the most common salivary gland surgery, but there remains a paucity of literature regarding its outcomes in the hands of surgical oncologists.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective review was conducted of all patients (n = 74) who underwent parotidectomy by surgical oncologists at a single institution over 10 years (2015–2025). Demographics, perioperative characteristics, and complications were compared. Associations between clinical factors and complications were evaluated by multivariate logistic regression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Most patients were White (85.1%) and male (51.4%) with a mean age of 59.9 years. The most common comorbidities were hypertension (48.6%), current smoking (40.5%), and anxiety (17.6%). Temporary facial nerve paresis occurred in 40.3% of patients by postoperative day one, with no cases of permanent facial nerve paresis. Frey's syndrome occurred in 9.0% and First Bite Syndrome (FBS) in 10.4% of tumor cases; a higher proportion of malignant cases experienced these complications in comparison to benign indications. Positive lymph node status was associated with FBS (<i>p</i> = 0.015), potentially reflecting more extensive surgical dissection. No significant risk factors were identified for other complications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study suggests that surgical oncologists with appropriate training can perform parotidectomies with complication rates within published ranges. Larger multicenter studies are needed to validate these findings and examine associations between clinical factors and rare complications, further establishing the role of surgical oncologists in parotidectomy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":"134 3","pages":"313-321"},"PeriodicalIF":1.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148156963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Routine Staging Laparoscopy for Pancreatic Adenocarcinoma in Underserved Populations: A 14-Year Experience at a Safety-Net Hospital","authors":"David M. Holmes,&nbsp;Jose Euberto Mendez Reyes,&nbsp;Cary Hsu,&nbsp;Eric J. Silberfein","doi":"10.1002/jso.70299","DOIUrl":"10.1002/jso.70299","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>There are no consensus guidelines for staging laparoscopy (SL) in pancreatic ductal adenocarcinoma (PDAC) and existing data largely reflect insured referral populations. Routine SL has not been studied in underserved patient populations who face disparities in cancer diagnosis and treatment. We evaluated the utility of SL for potentially operable PDAC at an urban safety-net hospital and assessed its association with survival.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A single-institution retrospective review was performed of all patients undergoing SL for potentially resectable PDAC (May 2011–May 2025). The primary outcome was detection of occult metastasis. Associated factors were assessed using multivariable logistic regression. Survival was analyzed using Kaplan–Meier methods and log-rank tests.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Fifty-two patients underwent SL and 18 (35%) received curative-intent surgery. Median age was 58 years, 87% were non-White, 40% non-English-speaking, and 89% presented emergently. SL identified occult metastatic disease in 12 patients (23.1%), including five (41.7%) identified by cytology alone. No clinicopathologic factors were associated with occult metastasis. Median overall survival was 9.5 months with occult metastasis versus 35.7 months without (<i>p</i> &lt; 0.001), and 102.5 months after curative-intent surgery versus 17.8 months without resection (<i>p</i> &lt; 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Routine SL frequently upstaged patients, often by cytology alone, thereby avoiding non-therapeutic laparotomy and supporting consideration of its more routine use in underserved PDAC populations.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":"134 3","pages":"330-336"},"PeriodicalIF":1.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jso.70299","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148199290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Classification of High- and Low-Risk Patients With Dermal Leiomyosarcoma: An Exploratory Nationwide Cohort Study","authors":"Kiya Abebe,&nbsp;Anders Munch,&nbsp;Anne Lene Wagenblast,&nbsp;Grethe Schmidt,&nbsp;David Hebbelstrup Jensen,&nbsp;Michael M. Petersen,&nbsp;Anand C. Loya,&nbsp;Søren Daugaard,&nbsp;Thomas Mentzel,&nbsp;Mikkel Herly,&nbsp;Peter Vester-Glowinski,&nbsp;Mathias Ørholt","doi":"10.1002/jso.70308","DOIUrl":"10.1002/jso.70308","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Risk factors for dermal leiomyosarcoma (dLMS) metastasis remain poorly defined because methodological constraints, small sample sizes, and short follow-up have limited previous studies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To investigate risk factors for metastasis and local recurrence, and to propose a high- and low-risk classification for dLMS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>All patients diagnosed with dLMS in Denmark between 1980 and 2022 were included. Absolute 5‑year risks were estimated using the Aalen-Johansen method, treating all‑cause mortality as a competing risk.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 381 patients (median age 66 years, 71% male), the 5-year risk of metastasis was 2.4% and 10% for local recurrence. The most important risk factors for metastasis were tumor necrosis, mitotic grade 3, and perineural/intravascular invasion, with 5-year absolute risks ranging between 9% and 25%. Positive surgical margins and perineural/intravascular invasion were associated with increased 5-year absolute risks of local recurrence, ranging between 26% and 50%.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Although few distant metastases were observed, high-risk dLMS features may include tumor necrosis, mitotic grade 3, perineural/intravascular invasion, or positive surgical margins. Cases without these features may be classified as low-risk dLMS. We propose regular cross-sectional imaging in the follow-up of patients with high-risk dLMS, whereas follow-up for patients with low-risk dLMS could be limited to clinical examinations.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":"134 3","pages":"394-402"},"PeriodicalIF":1.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jso.70308","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148258411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Factors for Patients Under 45 Undergoing Surgery for Colorectal Liver Metastases: A SEER Population-Based Study","authors":"Gabrielle Grob,&nbsp;Fang Fang,&nbsp;Matvey Karpov,&nbsp;Eric Feliberti,&nbsp;Marybeth Hughes,&nbsp;Rachel Burke,&nbsp;Winifred Lo","doi":"10.1002/jso.70300","DOIUrl":"10.1002/jso.70300","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Objectives</h3>\u0000 \u0000 <p>Colorectal cancer (CRC) has been on the rise in adults younger than 50. Surgical resection is a potentially curative treatment option for patients with colorectal liver metastases (CRLM). The aim of this study was to describe patient and tumor characteristics associated with disease-specific survival in young patients (&lt; 45 years) versus older patients (≥ 45 years) with isolated CRLM.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The SEER database was queried for patients with CRLM who underwent colon and liver resection from 2010 to 2021. Patients under age 20, with metastases beyond the liver, or who had not had surgery for liver metastases were excluded. Cox regression was used to analyze demographic factors, tumor characteristics, and treatment order.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The study group consisted of 2222 patients, with 299 patients less than 45 years old, and 1923 patients at least 45 years old. Higher nodal burden was associated with worse survival in both groups. Elevated CEA was associated with worse survival only in older patients. Younger patients experienced initial longer disease-specific survival.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Typical prognostic factors for older patients do not have the same impact on disease-specific survival for younger patients. Further study may help describe patient and tumor selection for surgical resection of colorectal liver metastases in young patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":"134 3","pages":"322-329"},"PeriodicalIF":1.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jso.70300","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148272069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Racial Differences in Breast Cancer Treatment and Information Access","authors":"Tokoya Williams,&nbsp;May X. Li,&nbsp;Keenan S. Fine,&nbsp;Bradley A. Melnick,&nbsp;Kelly C. Ho,&nbsp;Johna Joseph,&nbsp;Jayla Allums,&nbsp;Rolando J. Casas Fuentes,&nbsp;Brigid M. Coles,&nbsp;Robert D. Galiano","doi":"10.1002/jso.70304","DOIUrl":"10.1002/jso.70304","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Objectives</h3>\u0000 \u0000 <p>Persistent disparities in breast cancer (BC) care highlight the need to better understand patient experiences across diverse populations. This study examined racial differences in BC treatment, BR decisions, and social media use.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A web survey of 413 racially diverse breast cancer survivors collected self reported clinical data, BREAST-Q scores, and social media use. Multivariate regression examined BC treatment, BR complications, social media use, and satisfaction by race.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Black and Hispanic women were more likely to have mastectomy and chemotherapy than white women (<i>p</i> &lt; 0.01; <i>p</i> &lt; 0.001), even after adjusting for stage (<i>p</i> = 0.368). Asian women were less likely to receive chemotherapy or radiation (<i>p</i> &lt; 0.01). Despite more breast-conserving surgery (<i>p</i> &lt; 0.001 vs. Black; <i>p</i> &lt; 0.05 vs. Hispanic), white women reported lower breast satisfaction (<i>p</i> &lt; 0.05). Black and Hispanic women relied more on social media for information (<i>p</i> &lt; 0.001; <i>p</i> &lt; 0.01). Younger age, tobacco use, radiation, and comorbidities increased BR complication risk.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Women of color in this study experienced more aggressive treatment patterns and were more likely to rely on social media for information, highlighting an opportunity to address inequities in breast cancer care. Leveraging social media to deliver culturally tailored, evidence-based information may enhance understanding of treatment and surgical options, as well as complication risks, thereby promoting more equitable, patient-centered care.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":"134 3","pages":"383-393"},"PeriodicalIF":1.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jso.70304","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148391356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}